A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

• Status: RECRUITING
• Trial end date: 2030-03-25

Summary

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.

• Phase: PHASE3

Details

• Lead Sponsor: AstraZeneca
• Treatments: Carboplatin; Cisplatin; pembrolizumab; Pemetrexed